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Abstract 
Background   Autoimmune (type 1) diabetes (T1D) is a frequent chronic disease in children and 
adolescents globally. Gestational enterovirus (EV) infections have been associated with an 
increased risk for T1D in the offspring. We test the hypothesis that EV infections during the first 
trimester were associated with beta cell autoantibodies in mothers of children who developed 
islet autoantibodies before 7 years of age. 
 
Materials and Methods Local registries were used to identify mothers to children born 2000-
2007 who developed either beta cell autoantibodies or T1D during follow up. Serum samples 
from the first trimester were located in the Biobank. A total of 448 index mothers were identified 
and compared to 891 matched control mothers. EV-IgM was determined in a capture enzyme 
immunoassay. Beta cell autoantibodies were analyzed in standard radio binding assays.  
 
Results The frequency of EV-IgM in index mothers was 20% (89/448), which did not differ 
from the control mothers (20%; 175/891)(p=0.922). Index mothers had multiple beta cell 
autoantibodies more often than control mothers (p=0.037).   
Beta cell autoantibodies were increased during the November – April winter months in index 
compared to control mothers (p= 0.022). The observed difference was possibly explained by the 
months of February-April (p=0.014). Concomitant EV-IgM and beta cell autoantibodies tended 
to be more common among index compared to control mothers (p=0.039).  
 
Conclusion The present study reveals a possible interaction between EV-IgM and beta cell 
autoantibodies during the first trimester in mothers to children who developed either beta cell 
autoantibodies or T1D before 7 years of age.  
  
Funding Barndiabetesfonden, Stiftelsen Olle Engkvist Byggmästare, Sydvästra Skånes 
Diabetesförening, Lisa och Johan Grönbergs Stiftelse, Lunds Revisorer and HKH 
Kronprinsessan Lovisas förening för barnasjukvård. 
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1. Introduction 
Type 1 diabetes (T1D) is the result of autoimmune destruction of pancreatic beta cells. The 
disease is one of the most frequent chronic diseases in children and adolescents globally. The 
etiology of the disease has not been clarified but viruses have been considered an environmental 
factor that may induce a first beta cell autoantibody directed against either insulin (IAA), 
GAD65 (GADA), or both(Cabrera-Rode et al., 2003; Sarmiento, Cubas-Duenas, & Cabrera-
Rode, 2013). Following the appearance of a first autoantibody, multiple autoantibodies may 
appear as strong biomarkers of an immune pathogenic process leading to clinical onset of 
diabetes(Baekkeskov et al., 1987; Barker et al., 2004). (Eisenbarth, 2004) The appearance of a 
first beta cell autoantibody in the child may follow an EV infection(Sadeharju et al., 2001; 
Salminen et al., 2003). However, it has also been reported that EV infection may accelerate the 
pathogenesis resulting in a more rapid progress to clinical onset of diabetes(Beyerlein, 
Wehweck, Ziegler, & Pflueger, 2013; Hober & Sane, 2010; Hober & Sauter, 2010). Whether 
gestational EV infections also can be associated with an increased risk for beta cell 
autoimmunity and type 1 diabetes in the offspring is controversial(Dahlquist, Ivarsson, Lindberg, 
& Forsgren, 1995; Lindehammer, Hansson, et al., 2011; Tauriainen et al., 2007).  However, 
mothers with HLA-DQ 2/2 or 2/X genotypes showed an increased risk for beta cell 
autoantibodies at delivery. After adjusting for parity, maternal age, year of birth, and season of 
early pregnancy, early pregnancy EV-IgM combined with DQ2/2 or 2/X increased the risk for 
beta cell autoantibodies(Resic Lindehammer et al., 2012).  It is unclear if the risk for T1D in the 
offspring differs if the mother already had beta cell autoantibodies in early pregnancy or 
acquired them during pregnancy(Lernmark, Lynch, & Lernmark, 2006; Lindehammer, Hansson, 
et al., 2011).   
Our objective was to analyze EV-IgM along with GADA, IA-2A, and all three variants (amino 
acid R, W or Q at position 325) of ZnT8A in serum samples obtained from pregnant women 
during their first trimester. We test the overall hypothesis that concomitant exposure to EV and 
beta cell autoimmunity during the first trimester increased the risk for postpartum beta cell 
autoantibodies, T1D, or both.  
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2. Materials and Methods 
2.1 Study population  
The number of live births in the Skåne County between year 2000 and 2007 was 98,487, median 
per year: 12,277 and range between 11 151 - 13 837 per year (Figure 1).  Between October 2000 
and August 2004, 35,758 children were screened at birth in the Diabetes Prediction in Skåne 
(DiPiS) study(K. Larsson et al., 2004).  Between September 2004 and July 2007, 24,951 children 
were screened for The Environmental Determinants of Diabetes in the Young (TEDDY) study 
(Group, 2007).  Taken the two studies together, more than 5 000 children were followed either 
annually from two years of age in DiPiS or quarterly from 3 months of age in TEDDY(Group, 
2007; K. Larsson et al., 2004). In 2014, 688 children born 2000-2007 who had developed a beta 
cell autoantibody or T1D were identified.  
The Southern Sweden Microbiological Biobank (SSM-Biobank) has been collecting serum 
samples during the first trimester (gestational weeks 10-16) in >98% of all pregnant women in 
Skåne (Lindehammer, Hansson, et al., 2011; Ryding et al., 2008).  After confirmed pregnancy at 
the first visit to the Maternity Care Clinic, a blood sample was taken for the analysis of Rubella, 
HIV, Hepatitis B and Syphilis. The leftover sera were stored at - 20°C for up to 20 years in the 
SSM-Biobank for research purposes (Lindehammer, Hansson, et al., 2011; Ryding et al., 2008).   
It was possible to obtain the first trimester sample from 448/688 (65%) mothers (index mothers) 
giving birth to a child who during 2000-2014 had developed either a beta cell autoantibody or 
T1D (Figure 1). Of the 448 index mothers, 7 healthy mothers had beta cell autoantibodies, 21 
had T1D and 19 were diagnosed with gestational diabetes (Table 1).  There were seven samples 
with insufficient volumes (Figure 1).    
The control mothers were matched for age (+ 2 years), gender of the child, birth date of the child 
(+ 2 months) and birth place (hospital). Five control mothers for each index mother were first 
identified in the database of the screening for DiPiS and TEDDY, respectively. The next step 
was to find these mothers in the registry of SSM-Biobank. Here it was possible to select two 
control mothers for each index mother and in the final step we located samples from 905 control 
mothers in the actual sample repository. Of 891 available control mothers, 17 healthy mothers 
had beta cell autoantibodies, 9 were diagnosed with T1D, 2 were diagnosed with type 2 diabetes 
and 51 were diagnosed with gestational diabetes (Table 1). Insufficient serum volume made it 
necessary to exclude 14 control mothers (Figure 1).   
 
2.2 Enterovirus IgM analysis  
IgM class enterovirus antibodies were analysed using a capture EIA method and a mixture of 
three enterovirus antigens (Coxsackievirus B3, Echo11 and Coxsackievirus A16) as previously 
described
19
.  Briefly, microtiter plates (FISHER 10394751 (cat 439454) Nunc-immuno tm plate 
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maxisorp-levy MedixMAB™ anti-human IgM 7408 SPRN-5 (Kaupunki ei Cat.no 100084) were 
first coated over night with anti-human IgM monoclonal antibody (Anti-h IgM 7408 SPRN-5 
Medix Biochemica, Espoo, Finland), washed four times with EIA washing buffer and blocked 
with 0,1% BSA in PBS. Serum samples diluted 1/100 in EIA buffer were added and incubated 
for 1 hour at 37°C. The plates were washed 4 times with EIA washing buffer and heat 
inactivated virus antigen mixture (CVB3, ECHO11 and CAV16) was added in dilution 1/400 
and incubated for 30 minutes at 37°C. After washings, a mixture of biotinylated rabbit antibodies 
raised against each of the virus antigens CVB3/ECHO/CAV16 was added and incubated for 30 
minutes in room temperature. The plates were then washed 6 times with EIA washing buffer. 
Streptavidin-horseradish peroxidase conjugate (HRP-Conjugated Streptavidin, BD 
Pharmingen™, BD Biosciences, San Diego, CA, USA ) diluted 1/1000 in EIA buffer was added 
and incubated in dark for 30 minutes in room temperature. After the final washing a color 
reacting substrate (orto-phenylenediamine-dihydrochloride, Sigma-Aldrich, St. Louis, USA) was 
added, incubated in dark for 15 minutes in room temperature, stopped with H2SO4 and the 
absorbances were read at 490 nm.  
The cut-off for being enterovirus IgM positive was the level of background control multiplied by 
four. In addition, a less stringent cut-off (three times the absorbance of the background) was used 
in sensitivity analyses. The analyzing laboratory was blinded to the identity of the samples.  
 
2.3 Beta cell autoantibody assay  
Coupled in vitro transcription and translation was performed using the TNT SP6 coupled 
reticulocyte lysate system (Promega, Southhampton, UK)
 (Kjelleras, Vaziri-Sani, & Agardh, 2011)
. 
Established standardized radioligand assays were used to determine the autoantibody levels to 
GADA, IA-2A and ZNT8A as previously described(Grubin et al., 1994). Briefly, serum samples, 
diluted 1/25 in antigen buffer were incubated with 
35
S-methionine labeled GAD65, IA-2 or ZnT8 
over night at +4°C in 96 well plates. The reaction mixture was transferred to filtration plates and 
incubated +4°C for 1 hour with 50 uL 20% Protein A Sepharose (Thermo Fisher Scientific, 
Waltham, MA USA) suspended in antigen buffer on a plate shaker. Unbound antigen was 
removed by washing and the radioactivity of Protein A Sepharose antibody-bound antigen 
counted in a Microbeta Trilux 1450-021 (PerkinElmer, Waltham, Massachusetts, USA) (Grubin 
et al., 1994). 
Levels of beta cell autoantibodies in the maternal first trimester serum samples were determined 
from the international WHO standard of GADA and IA-2A (PMID: 10398550) defining titers in 
units/mL (U/mL).  
The cut-off was defined at the 98th percentile for GADA, 99.0th percentile for IA-2A and the 
99.5th percentile for ZNT8A from the control serum samples. Our laboratory is participating in 
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the Islet Autoantibody Standardization Program (IASP) (H. E. Larsson et al., 2008; Torn et al., 
2008). In the last workshop our GADA radiobinding assay showed a workshop sensitivity of 
54.0% and workshop specificity of 98.9%.  In the IA-2A assay sensitivity was 74.0% and 
specificity 100%; ZnT8RA, 52.0% and 98.9%, respectively, ZnT8WA, 48.0 % and 98.9%, and 
ZnT8QA, 38.0 % and 98.9%, respectively. 
 
2.4 Statistical analysis  
Sample size and power calculation: Prior data indicate that the probability of exposure among 
controls is P0 = 0.10 and the correlation coefficient for exposure between matched index and 
control mothers is θ = 0.25.  We will be able to detect true odds ratios for disease of 0.59 or 1.58 
in exposed subjects relative to unexposed subjects with probability (power) 0.8. The Type I error 
probability associated with this test of the null hypothesis that this odds ratio equals 1 is 0.05.) 
SPSS 24
®
 statistical package (SPSS Inc. IBM, Chicago, Illinois, US) was used for X
2
 and 
Fishers exact test calculation and comparison of the frequency of IgM and IA positivity between 
index and control mothers.   
 
Study approval: The study was approved by the Ethical committee in Lund, Sweden (Decision 
number 2011/475). 
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3. RESULTS 
3.1 Enterovirus IgM levels and frequencies 
Serum available from a total of 448 index and 891 control mothers were analyzed for 
Enterovirus IgM (EV-IgM) (Figure 1; Table 1).  The frequency of EV-IgM was 20% in both 
index and control mothers (p=0.92, Table 2). While healthy mothers (group A) and healthy 
mothers with beta cell autoantibodies (Group B) did not differ in EV-IgM, it was found that 
Group C index (24%) but not control (0%) mothers with type 1 diabetes had EV-IgM (p= 0.29).  
Mothers with gestational diabetes (Group D) did not differ in frequency (21% compared to 26%, 
p=01).  
The seasonal variation of EV-IgM in groups A-E, divided bi-annually (Nov-Apr; p=0.522 and 
May-Oct p=0.487 respectively) as well as further divided quarterly (Nov-Jan; p=0.661, Feb-Apr; 
0.755, May-Jul; p=1 and Aug-Oct: p=0.310 (Supplementary Table 1) revealed no difference 
between index and control mothers.   
 
3.2 Levels of beta cell autoantibodies 
Beta cell autoantibody levels are illustrated in Supplementary Figure 1. The median levels of 
GADA were 8 (range 3- 1393) U/mL U/mL in index (n=431) and 7 (1- 1082U/mL in control 
(n=868) mothers, (p=0.014). GADA were detected in 21/431 (4.9%) index compared to 16/868 
(1.9%) controls mothers (p=0.002).  
The median levels of IA-2A in index (n=431) were 3 (1- 1158 U/mL,) and 2 (1- 473) U/mL   in 
control mothers (n=868, p=0.006). IA-2A was detected in 13/431 (3.0%) index compared to 
8/868 (0.9%) controls mothers (p=0.005). ZnT8A median levels in index (n=431) were 26 (1-
1166) U/mL () and 25 (5-1006) U/mL in control mothers (n=867, p<0.001) The ZnT8A 
frequencies at the 99.5
th 
percentile was 5/431 (1.2%) in index and 4/867 (0.5%) in control 
mothers (p=0.168).  
 
3.3 Beta cell autoantibody frequencies   
The numbers of GADA, IA-2A or ZnT8A antibodies in index and control mothers are illustrated 
in Supplementary Table 3. Index mothers in group B were either single (n=6,) or double (n=1) 
positive compared to single (n=15), double (n=1;) or triple (n=1) positive (p= 0.064664).  
In mothers reporting type 1 diabetes (Group C), index and control mothers were single (n=8, 5 
GADA and 3 IA-2A) or double (n=7; 6 GADA and IA-2A as well as 1 GADA and ZNT8A) or 
triple (n=3) positive compared to single (n=5; 4 GADA, 1 IA-2A) or triple (n=1) positive 
(p=0.177, Supplementary Figure 1). Adding group B and C together revealed that index had 
more beta cell autoantibodies alone or in combination compared to control mothers (p=0.037).  
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None of the mothers in group A (Healthy Mothers), group D (Mothers with Type 2 Diabetes) or 
E (Mothers with gestational diabetes) had any beta cell autoantibody (Supplementary Table 2).  
The seasonal variation of beta cell autoantibodies in groups A-E indicated an increase frequency 
during the winter months Nov-Apr among index compared to control mothers (p= 0.022, 
Supplementary Table 3). The observed difference was possibly explained by the months of Feb-
Apr (p=0.014).  
 
3.4 EV- IgM and beta cell autoantibody frequencies combined 
The frequency of IgM combined with beta cell autoimmunity is summarized in Table 3. Groups 
were divided into IgM and IA double negative (index n=325, controls n=680), IgM positive and 
IA negative (index n=81, controls n=166), IgM negative and IA positive (index n=19, controls 
n=19) , IgM positive and IA positive (index n=6, controls n=4) and analyzed for the total 
distribution (p=0.039).  
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4. Discussion  
The major findings in the present study of EV-IgM and beta cell autoantibodies during the first 
trimester in index mothers giving birth to children who after one year of age had developed beta 
cell autoantibodies or type 1 diabetes indicate that beta cell autoimmunity was increased in index 
compared to control mothers. In the beta cell autoantibody positive mothers, it cannot be 
excluded that EV-IgM was more common compared to the control mothers. It is therefore 
possible to speculate that EV-IgM and beta cell autoantibodies during the first trimester may be 
associated with an increased risk for the offspring to develop beta cell autoimmunity and type 1 
diabetes. The combination of EV-IgM and beta cell autoimmunity suggest that these mothers 
may have experienced an EV infection that is somehow related to beta cell autoimmunity 
affecting the fetus that it is prone to develop beta cell autoimmunity postpartum. Recent data 
suggest that the appearance of two or more beta cell autoantibodies was associated with 70% risk 
for type 1 diabetes within 10 years (Ziegler et al., 2013).   
 
In interpreting our data, there are two possibilities. First, EV-IgM may have induced beta cell 
autoantibodies during the first trimester.  The problem with this interpretation is that beta cell 
autoantibodies are of the IgG type. Hence, these autoantibodies tend to be persistent over months 
and years. A concomitant seroconversion would therefore be unexpected. Second, the other 
possibility is therefore that the EV-IgM suggests a relatively recent infection in an asymptomatic 
beta cell autoantibody positive mother.  
 
The frequency of Enteroviral IgM antibodies did not differ between diabetes and control 
mothers. This in conjunction with the rather high positivity rates (20 and 19.7% respectively) 
suggests additional genetic and possibly environmental triggers. A weakness of our study is the 
lack of genetic information, preferably HLA-type of the mothers and their offspring. We observe 
a seasonal pattern regarding IA-2A autoantibody levels and the birth-month of child; high levels 
were seen for the first 7 months of the year. To our knowledge this has not been reported before; 
children born early during the year means samples were taken during the autumn months. A 
seasonal pattern for enterovirus infections and the closely related parechovirus having a peak 
during the summer and autumn has been reported(Fischer, Midgley, Dalgaard, & Nielsen, 2014; 
Nielsen, Bottiger, Midgley, & Nielsen, 2013). Additional studies are needed to record seasonal 
patterns with seroconversion of beta cell autoantibodies
28
.  
 
Previous studies(Dahlquist et al., 1995; Lindehammer, Hansson, et al., 2011; Tauriainen et al., 
2007; Viskari et al., 2012) have investigated and suggested a link between Enterovirus infections 
and the subsequent appearance of beta cell autoantibodies in the mother during pregnancy. It was 
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not possible in the present study to confirm these earlier findings as samples from the third 
trimester or at delivery were not available. The information of the beta cell autoantibody and 
type 1 diabetes status in the offspring from this 7-year cohort of first trimester mothers were 
validated through several studies. First, in mothers who gave birth to children in 2000-2004, we 
used the follow-up data in the DiPiS study(H. E. Larsson et al., 2008; Lundgren et al., 2014; 
Lynch et al., 2008) for beta cell autoantibodies and the national registry (Hanas, Lindgren, & 
Lindblad, 2007)for type 1 diabetes. Second, in mothers giving birth in 2004-2007 we used the 
follow-up data from the Swedish children enrolled in the TEDDY study(Krischer et al., 2015).   
In a previous Finnish study with the same objective as in the present study, an enterovirus 
infection was reported in 19.3% among their index mothers, a frequency similar to ours 
(20.0%)(Viskari et al., 2012). It´s noted that the numbers for the control-groups differ (Viskari 
et.al 12.0%-present study 19.0%). Whether a country-specific difference, the methodology of the 
studies or other factors explain the difference for the control-groups is not known.   
 
The etiology behind type 1 diabetes is complex with several environmental triggers in 
combination with HLA-genes contribute to the development not of diabetes as such but rather 
the appearance of a first appearing beta cell autoantibody to be followed by a prolonged period 
of asymptomatic beta cell autoimmunity that precede the clinical onset. Based on our results, it’s 
possible to speculate of an IgM enterovirus infection in a subgroup of the index mothers with 
beta cell autoantibodies during the first trimester may have increased the risk of the offspring to 
develop beta cell autoantibodies and type 1 diabetes.   The TEDDY study reported recently that 
gestational respiratory infections showed a consistent protective influence on IAA among 
children with the G allele in CTLA4 (ref: Lynch et al. 2017). The authors concluded that the role 
of gestation respiratory infections may depend on offspring HLA and CTLA-4 alleles and 
supports a bidirectional trigger for IAA or GADA as a first appearing β-cell autoantibody in 
early life (Lynch et al. 2017). It can therefore not be excluded that some of our mothers have had 
an infection during pregnancy that markedly affected the risk of the offspring to develop a beta 
cell autoantibody before 7 years of age.  
 
A difference in beta cell autoantibody positivity between index (later giving birth to a child who 
developed diabetes) and controls mothers were related especially to the Scandinavian winter-
months (October-March). This seasonal variation is in line with previous studies and of possible 
importance since Enteroviruses is also associated to this season(Lynch et al., 2008). Further 
investigations of the birth-month of the children suggested a seasonal variation to the summer-
months (July, August, September).  
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Of importance, the frequency of IgM positive individuals was 24% (5/21) in index mothers with 
Type 1 diabetes compared to 0% (0/9, precluding statistical calculations) controls mothers. It’s 
well known that the risk of a child to develop type 1 diabetes is increased with an affected 
parent(Dahlquist et al., 1995). This is most likely due to genetic interacting with environmental 
factors. 
 
Increased levels of serum cytokines in early pregnancy might increase the risk of type 1 diabetes 
in the offspring. If cytokines are markers for infection, further studies are needed evaluate if it is 
Enteroviral or parechoviralinfection (Lindehammer, Fex, et al., 2011). Recent study from our 
research group indicates that the presence of cord blood IA-2A autoantibodies was associated 
with an increased risk for type 1 diabetes in the child(Lundgren et al., 2014) .  
Our results did not support the suggested association between enterovirus infection and 
development of Type 1 diabetes. These mothers with autoantibodies, giving birth to children 
with diabetes have no association to Enterovirus IgM primary infection in similarity to previous 
studies.  
 
It’s of interest that mothers with type 1 diabetes could be associated with an increased beta cell 
autoantibody frequency but not increased Enterovirus IgM antibody frequency. This suggests 
further research of antibody measurements as a preferable diagnostic tool compared to 
Enterovirus IgM antibody measurements when screening for early risk diabetic biomarkers. 
Whether beta cell autoantibodies do pass the placenta from mother to child or whether the 
genetic HLA association is to explain the association between increased autoantibodies in 
mothers and development of diabetes in the child is currently not known.  
 
5. Conclusion 
The results of our study do not suggest that maternal enterovirus infection during first trimester 
of the pregnancy should be considered as a risk factor for beta cell autoimmunity and type 
1diabetes in the offspring. However, based on our key observations; 1) a difference between 
index and control mothers in the distribution of combined IgM antibodies and beta cell 
autoantibody frequency; and 2) increased frequency of IgM positive individuals among Type 1 
diabetes index mothers, it cannot be excluded that enteroviruses contribute to the disease 
etiology in a subgroup of patients.  
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Table 1. Study participants and their demographic characteristics    
 Index mothers Control mothers 
Total number of subjects 448 
 
891 
A. Healthy mothers  
Age (median and range) 
401 
(30,19-43) 
812 
(30,18-43) 
B .Healthy Mothers with  
Beta cell autoantibodies  
Age (median and range) 
7 
(33,26-35) 
17 
(32,24-39) 
C .Mothers with Type 1 diabetes 
Age (median and range) 
21 
(31, 23-37) 
9 
(32, 20-37) 
D .Mothers with  
Type 2 diabetes 
Age (median and range) 
                       --- 
                      
2 
(32.5, 32-33) 
E. Mothers with gestational  
diabetes (GDM) 
Age (median and range) 
19  
(32,26-39) 
51 
(32,22-42)  
 
 
Table 2.  Frequency of EV-IgM in index and control mothers.  
 Index mothers Control mothers p-value  
Total number of subjects 89/448 (20%) 175/891 (20%) 
 
       0.922 
A. Healthy mothers 
 
79/401 (20%) 157/812 (19%)  0.88 
B. Healthy mothers with  
beta cell Autoantibodies  
1/7 (14%) 4/17 (24%)  1 
C. Mothers with Type 1 diabetes 5/21 (24%) 0/9 (0%) 0.29 
D. Mothers with Type 2 diabetes --- 1/2 (50%) --- 
E. Mothers with gestational 
diabetes (GDM) 
4/19 (21%) 13/51 (26%) 1 
Fischer exact test was used for p-value.  
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Table 3. EV- IgM and beta cell autoantibodies in index and control mothers. 
EV-IgM IA (all 3) Index (%) Controls (%)  
- - 325 (75) 680 (78)  
+ - 81 (19) 166 (19)  
- + 19 (4) 19 (2)  
+ + 6 (2) 4 (1)  
            431(100) 869 (100) 1300 (p=0.039) 
Fischer exact test was used for p-value.  
 
 
 
 
 
 
 
 
  
 
     
 
 
       
        
        
  
 
             
        
  
 
     
        
        
        
        
  
 
     
  
      
  
 
 
 
   
        
 
 
  
 
   
        
        
  
 
     
        
        
 
 
      
        
        
        
        
 
 
 
 
     
       
 
   
   
  
 
     
        
        
 
  
     
        
        
         
 
10/2000 - 7/2007 
98.487 Births in Skåne 
Children with 
T1D (n = 99)  
or islet 
autoantibodies 
(n = 589) 
Index mothers 
n = 688 
Children with no 
T1D or 
autoimmunity 
Control mothers  
n = 1367 
SSM Biobank  
Index mothers 
sera available 
n = 455 
Control mothers 
sera available 
n = 905 
 
Index mothers 
for EV IgM  
n = 448 
(69 T1D and 379 islet 
autoantibodies) 
 
Control mothers 
for EV IgM  
n = 891  
7sera excluded – 
insufficient volume 
14 sera excluded – 
insufficient volume 
DiPiS and TEDDY  
59.802 (61%) Mothers 
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